2014 Year In Review Of US Biosimilar Activity
This year witnessed significant activity in the U.S. with respect to biosimilars. Highlights include issuance by the U.S. Food and Drug Administration of two new guidances, further debate over the naming...To view the full article, register now.
Already a subscriber? Click here to view full article